|
|
|||||||||||||||||||||||||||
  LogicBio Therapeutics Inc (LOGC) LogicBio Therapeutics is a clinical-stage genetic medicine company focused on genome editing and gene delivery platforms to address diseases from infancy through adulthood. Co.'s genome editing platform, GeneRide™, is an approach to gene insertion harnessing a cell's natural deoxyribonucleic acid repair process. Co.'s product candidate, LB-001, is a single-administration, genome editing therapy developed using its GeneRide technology for the treatment of methylmalonic acidemia in pediatric patients. Co.'s other product candidate, LB-401 is based on its GeneRide technology. LB-401 is a genome editing therapy being developed for the treatment of hereditary tyrosinemia type 1 in newborns.
|
|
|||||||||||||||||||||||||||
Free LOGC Email Alerts:
LogicBio Therapeutics Inc (LOGC) Page | The Online Investor | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.